524P A phase I, open-label, dose-escalation trial of BI 1701963 in patients (pts) with KRAS mutated solid tumours: A snapshot analysis
Melissa L. Johnson, Eelke Gort, Shubham Pant, Martijn P. Lolkema, Martin Sebastian, Matthias Scheffler, Justin H. Hwang, Ulrich Dünzinger, K. Riemann, Thomas Kitzing, Pasi A. Jänne
Topics & Concepts
MedicineKRASAdverse effectInternal medicineOpen labelGastroenterologyDiscontinuationColorectal cancerCancerPeptidase Inhibition and AnalysisChronic Lymphocytic Leukemia ResearchBiochemical and Molecular Research